PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19939455-7 2010 Treg activation by IL-2 induced a strong AC7 activation and cAMP accumulation in Treg. Cyclic AMP 60-64 interleukin 2 Mus musculus 19-23 23785120-1 2013 Transcription factor cAMP response element modulator (CREM)alpha contributes to various cellular and molecular abnormalities in T cells, including increased IL-17 and decreased IL-2 expression. Cyclic AMP 21-25 interleukin 2 Mus musculus 177-181 19949065-8 2010 These findings could not be solely attributed to an observed perforin deficiency in freshly isolated Camp(-/-) NK cells, because this deficiency could be partially restored by IL-2 treatment, whereas cytotoxic activity was still defective in IL-2-activated Camp(-/-) NK cells. Cyclic AMP 257-261 interleukin 2 Mus musculus 242-246 10092780-5 1999 IL-2 increased the expression of cytoskeleton proteins (alpha-tubulin), oncogene-regulating proteins (CCCTC-binding factor, Jun inhibitor factor-1), and transcription factors (E2F-4, cyclic AMP-responsive element-binding protein, zhx-1). Cyclic AMP 183-193 interleukin 2 Mus musculus 0-4 15240680-0 2004 Adenosine acts through A2 receptors to inhibit IL-2-induced tyrosine phosphorylation of STAT5 in T lymphocytes: role of cyclic adenosine 3",5"-monophosphate and phosphatases. Cyclic AMP 120-156 interleukin 2 Mus musculus 47-51 11404394-2 2001 Our data show that cAMP-mediated inhibition of endogenously expressed cytokines, which is characteristic for T helper (Th) 1- and Th 2-like phenotypes, correlates with the induction of a potent transcriptional repressor, inducible cAMP early repressor (ICER), in both subsets of T cells activated under conditions of suboptimal interleukin-2 (IL-2) expression. Cyclic AMP 19-23 interleukin 2 Mus musculus 328-341 11404394-2 2001 Our data show that cAMP-mediated inhibition of endogenously expressed cytokines, which is characteristic for T helper (Th) 1- and Th 2-like phenotypes, correlates with the induction of a potent transcriptional repressor, inducible cAMP early repressor (ICER), in both subsets of T cells activated under conditions of suboptimal interleukin-2 (IL-2) expression. Cyclic AMP 19-23 interleukin 2 Mus musculus 343-347 16514061-3 2006 Gene ablation of PKCtheta selectively results in a profound reduction of IL-2 production; however, complete abrogation of IL-2 production in these PKCtheta(-/-) T cells was achieved only by simultaneous coactivation of the cAMP/PKA pathway in CD3(+) T cells. Cyclic AMP 223-227 interleukin 2 Mus musculus 122-126 16514061-4 2006 Conversely, the reduced IL-2 production in PKC inhibitor-treated T cells can be rescued by inhibition of the cAMP/PKA pathway in wild-type but not in PKCtheta(-/-) T cells. Cyclic AMP 109-113 interleukin 2 Mus musculus 24-28 16514061-8 2006 Taken together, this opposite effect between the positive PKCtheta and the negative cAMP/PKA signaling pathways appears rate limiting for NF-AT transactivation and IL-2 secretion responses of CD3(+) T lymphocytes. Cyclic AMP 84-88 interleukin 2 Mus musculus 164-168 12892052-1 2003 We have shown previously that the elevation of intracellular cAMP in antigen or anti-CD3-activated murine Th1 clones in the absence of antigen inhibits antigen-induced proliferation and the production of IL-2 by H2O2-mediated oxidation of p56lck and inhibits antigen-induced production of interferon-gamma by the induction of intracellular nitric oxide. Cyclic AMP 61-65 interleukin 2 Mus musculus 204-208 9208143-2 1997 We have investigated the suppressive effects of rolipram, RP 73401 (piclamilast) and other structurally diverse inhibitors of cyclic AMP-specific phosphodiesterase 4 (PDE4) on interleukin (IL)-2 generation from Balb/c mouse splenocytes exposed to the superantigen, Staphylococcocal enterotoxin-A (Staph. Cyclic AMP 126-136 interleukin 2 Mus musculus 176-194 8993475-4 1996 Comparisons with forskolin, a known cAMP inducer, suggest that the increase in intracellular cAMP represents at least one of the transduction pathways involved in IL-2 inhibition, especially in the higher range of neuropeptide concentration. Cyclic AMP 36-40 interleukin 2 Mus musculus 163-167 9171236-5 1997 Reduction of IL-2 production is secondary to the inability to phosphorylate the cAMP response element binding protein, CREB, and induce expression of the immediate early genes such as Fos B that are required to transactivate the IL-2 promoter. Cyclic AMP 80-84 interleukin 2 Mus musculus 13-17 8993475-4 1996 Comparisons with forskolin, a known cAMP inducer, suggest that the increase in intracellular cAMP represents at least one of the transduction pathways involved in IL-2 inhibition, especially in the higher range of neuropeptide concentration. Cyclic AMP 93-97 interleukin 2 Mus musculus 163-167 8662742-2 1996 In the present studies, signaling via the adenylate cyclase/cAMP pathway was investigated in the murine thymoma-derived T-cell line, EL4.IL-2. Cyclic AMP 60-64 interleukin 2 Mus musculus 137-141 8648100-4 1996 CRE binding was markedly induced after 48 h; it gradually declined at 72 h, but remained elevated above control levels after 120 h. Most significant, activation by anti-CD3 was associated with a marked induction of cAMP levels that preceded the onset of DNA synthesis and the induction of IL-2 secretion and reached a peak after 48 h (9.5- to 11-fold), concomitant with the peak in CRE binding. Cyclic AMP 215-219 interleukin 2 Mus musculus 289-293 9051743-4 1996 Furthermore, IL-2 significantly inhibited cAMP production stimulated by forskolin in both NG 108-15 and transfected HEK 293 cells, indicating that the binding of IL-2 to the delta opioid receptor is functional. Cyclic AMP 42-46 interleukin 2 Mus musculus 13-17 8662742-5 1996 Treatment of EL4.IL-2 cells with either cannabinol or Delta9-THC disrupted the adenylate cyclase signaling cascade by inhibiting forskolin-stimulated cAMP accumulation which consequently led to a decrease in protein kinase A activity and the binding of transcription factors to a CRE consensus sequence. Cyclic AMP 150-154 interleukin 2 Mus musculus 17-21 8662742-9 1996 These findings suggest that inhibition of signal transduction via the adenylate cyclase/cAMP pathway induces T-cell dysfunction which leads to a diminution in IL-2 gene transcription. Cyclic AMP 88-92 interleukin 2 Mus musculus 159-163 7592673-2 1995 Accumulating evidence suggests a role for cAMP as an immunomodulator; agents that increase intracellular cAMP levels have been shown to inhibit production of cytokines predominantly produced by T helper (Th) 1 cells such as IL-2 and interferon gamma (IFN-gamma). Cyclic AMP 42-46 interleukin 2 Mus musculus 224-228 8543769-1 1995 Cyclic adenosine monophosphate (cAMP) inhibits phorbol 12-myristate 13-acetate (PMA)-induced IL-2 production while it inhibits IL-5 production at the transcriptional level in EL-4, a mouse lymphoma line. Cyclic AMP 0-30 interleukin 2 Mus musculus 93-97 8543769-1 1995 Cyclic adenosine monophosphate (cAMP) inhibits phorbol 12-myristate 13-acetate (PMA)-induced IL-2 production while it inhibits IL-5 production at the transcriptional level in EL-4, a mouse lymphoma line. Cyclic AMP 32-36 interleukin 2 Mus musculus 93-97 8543769-2 1995 The -321 to +46 region of the mouse IL-2 promoter is required for activation by PMA and inhibition by cAMP. Cyclic AMP 102-106 interleukin 2 Mus musculus 36-40 7592673-2 1995 Accumulating evidence suggests a role for cAMP as an immunomodulator; agents that increase intracellular cAMP levels have been shown to inhibit production of cytokines predominantly produced by T helper (Th) 1 cells such as IL-2 and interferon gamma (IFN-gamma). Cyclic AMP 105-109 interleukin 2 Mus musculus 224-228 7819141-8 1994 This is supported by the fact that complex formation between a synthetic nuclear factor of activated T cells (NF-AT) binding site from the IL-2 promoter and nuclear extracts was decreased when cholera toxin was added to re-activated CD4+ T cells, suggesting that cholera toxin and cAMP down-regulate IL-2 expression via decreased NF-AT binding. Cyclic AMP 281-285 interleukin 2 Mus musculus 139-143 7986157-7 1994 Incubation of normal splenocytes with dibutyryl cAMP in the presence of concanavalin A significantly decreased cell proliferation and the production of interleukin-2. Cyclic AMP 48-52 interleukin 2 Mus musculus 152-165 7819141-0 1994 cAMP up-regulates IL-4 and IL-5 production from activated CD4+ T cells while decreasing IL-2 release and NF-AT induction. Cyclic AMP 0-4 interleukin 2 Mus musculus 88-92 7730629-0 1995 Cyclic AMP inhibits expression of the IL-2 gene through the nuclear factor of activated T cells (NF-AT) site, and transfection of NF-AT cDNAs abrogates the sensitivity of EL-4 cells to cyclic AMP. Cyclic AMP 0-10 interleukin 2 Mus musculus 38-42 7730629-1 1995 cAMP inhibits PMA-induced IL-2 production at the transcriptional level in EL-4, a mouse lymphoma line. Cyclic AMP 0-4 interleukin 2 Mus musculus 26-30 7730629-2 1995 The region of the mouse IL-2 promoter covering positions from -321 to +46 relative to the transcription initiation site is required for activation by PMA and inhibition by cAMP. Cyclic AMP 172-176 interleukin 2 Mus musculus 24-28 7730629-4 1995 The IL-2 promoter carrying mutations in each element reduced response to PMA while it retained sensitivity to cAMP, thereby suggesting that multiple elements contribute to positive and negative responses to PMA and cAMP, respectively. Cyclic AMP 110-114 interleukin 2 Mus musculus 4-8 7730629-4 1995 The IL-2 promoter carrying mutations in each element reduced response to PMA while it retained sensitivity to cAMP, thereby suggesting that multiple elements contribute to positive and negative responses to PMA and cAMP, respectively. Cyclic AMP 215-219 interleukin 2 Mus musculus 4-8 7730629-10 1995 Taken together, our data show that cAMP in EL-4 cells inhibits mouse IL-2 gene transcription through cis regulatory elements that include the NF-AT site as well as the NF-kappa B site. Cyclic AMP 35-39 interleukin 2 Mus musculus 69-73 1330897-0 1992 Interleukin-2 may enhance or inhibit antibody production by B cells depending on intracellular cAMP concentrations. Cyclic AMP 95-99 interleukin 2 Mus musculus 0-13 8083467-4 1994 In contrast, cAMP almost completely inhibited the PMA-dependent activation of the endogenous IL-2 gene, as well as the transfected IL-2 promoter. Cyclic AMP 13-17 interleukin 2 Mus musculus 93-97 8083467-4 1994 In contrast, cAMP almost completely inhibited the PMA-dependent activation of the endogenous IL-2 gene, as well as the transfected IL-2 promoter. Cyclic AMP 13-17 interleukin 2 Mus musculus 131-135 8210948-2 1993 The results indicate that, at the late phase of IL-2 induction, LAK cells retain their responsiveness to PGE2 inhibition, and the inhibition can be partially suppressed by additional IL-2 in proportion to the decrease in the ratios of stimulated to basal cellular cAMP levels. Cyclic AMP 264-268 interleukin 2 Mus musculus 183-187 1383217-4 1992 We present evidence that CGRP induces a dose-dependent cAMP accumulation in interleukin 2-producing TH1 cells and inhibits their production of interleukin 2. Cyclic AMP 55-59 interleukin 2 Mus musculus 76-89 1330897-3 1992 IL-2 inhibits the cyclic adenosine 3",5"-phosphate (cAMP)-dependent B-cell response when it is allowed to act on the cells prior to cAMP. Cyclic AMP 18-50 interleukin 2 Mus musculus 0-4 1330897-3 1992 IL-2 inhibits the cyclic adenosine 3",5"-phosphate (cAMP)-dependent B-cell response when it is allowed to act on the cells prior to cAMP. Cyclic AMP 52-56 interleukin 2 Mus musculus 0-4 1330897-3 1992 IL-2 inhibits the cyclic adenosine 3",5"-phosphate (cAMP)-dependent B-cell response when it is allowed to act on the cells prior to cAMP. Cyclic AMP 132-136 interleukin 2 Mus musculus 0-4 1330897-4 1992 On the other hand, if IL-2 acts on B cells together with or after cAMP, it synergizes with the nucleoside and enhances the immune response. Cyclic AMP 66-70 interleukin 2 Mus musculus 22-26 1330897-7 1992 The inhibitory IL-2 effect is reversed by the simultaneous addition of exogenous cAMP. Cyclic AMP 81-85 interleukin 2 Mus musculus 15-19 1330897-13 1992 IL-2 inhibits both of these B-cell responses to cAMP, the IL-1-independent cell death, and the IL-1-dependent phenotypic differentiation. Cyclic AMP 48-52 interleukin 2 Mus musculus 0-4 1646113-10 1991 These data provide evidence that IL 2 acts in CTL through a mechanism independent of cholera toxin-sensitive GTP-binding protein in vitro and in vivo, despite elevated intracellular cAMP levels. Cyclic AMP 182-186 interleukin 2 Mus musculus 33-37 2475434-4 1989 Incubation of 4b.14a cells with syngeneic antigen-presenting cells, previously pulsed with the 89-101 synthetic peptide or with 80 U/ml of IL-2, or allogeneic H-2Ik cells, resulted in a significant increase in the accumulation of intracellular cAMP. Cyclic AMP 244-248 interleukin 2 Mus musculus 139-143 1715770-3 1991 Agents that elevated intracellular cAMP blocked or partially blocked IL-1 induction of IL-2 secretion, whereas agents that activated protein kinase C (PKC) resulted in a synergistic enhancement. Cyclic AMP 35-39 interleukin 2 Mus musculus 87-91 1646113-2 1991 Because increases in intracellular cAMP inhibit interleukin 2 (IL 2) expression and cytotoxic T lymphocyte (CTL) generation and function in vitro and in vivo, we hypothesized that IL 2 may counteract the inhibition of CTL by cholera toxin. Cyclic AMP 35-39 interleukin 2 Mus musculus 48-61 1646113-2 1991 Because increases in intracellular cAMP inhibit interleukin 2 (IL 2) expression and cytotoxic T lymphocyte (CTL) generation and function in vitro and in vivo, we hypothesized that IL 2 may counteract the inhibition of CTL by cholera toxin. Cyclic AMP 35-39 interleukin 2 Mus musculus 63-67 1646113-2 1991 Because increases in intracellular cAMP inhibit interleukin 2 (IL 2) expression and cytotoxic T lymphocyte (CTL) generation and function in vitro and in vivo, we hypothesized that IL 2 may counteract the inhibition of CTL by cholera toxin. Cyclic AMP 35-39 interleukin 2 Mus musculus 180-184 2174560-0 1990 cAMP inhibits induction of interleukin 2 but not of interleukin 4 in T cells. Cyclic AMP 0-4 interleukin 2 Mus musculus 27-40 2174560-2 1990 Elevation of cAMP levels blocks IL-2 induction while sparing IL-4 induction. Cyclic AMP 13-17 interleukin 2 Mus musculus 32-36 2840461-6 1988 Stable analogues of cAMP which inhibit IL-2-stimulated proliferation, suppressed only the mRNA-dependent increase in ODC activity. Cyclic AMP 20-24 interleukin 2 Mus musculus 39-43 2521509-9 1989 As was found with PGE2, these compounds also induced GM-CSF activity in the presence of IL-2, suggesting a critical role for cAMP in this process. Cyclic AMP 125-129 interleukin 2 Mus musculus 88-92 2562439-2 1989 IL-2-induced proliferation was inhibited by membrane-permeable dibutyryl cyclic adenosine monophosphate (cAMP) or by the adenylate cyclase activator forskolin. Cyclic AMP 105-109 interleukin 2 Mus musculus 0-4 2562439-3 1989 Consistent with these observations was the finding that stimulation with IL-2 decreased and forskolin increased the intracellular content of cAMP. Cyclic AMP 141-145 interleukin 2 Mus musculus 73-77 2846687-9 1988 The ability of CT to inhibit much more effectively the proliferation triggered by putative activators of PKC than that induced by IL-2 may be mediated by cAMP-dependent mechanisms. Cyclic AMP 154-158 interleukin 2 Mus musculus 130-134 3005278-3 1986 In intact cells, IL 2 inhibited both basal and PGE2-stimulated cAMP production; the amount of cAMP generated was dependent upon the relative concentrations of IL 2 and PGE2. Cyclic AMP 63-67 interleukin 2 Mus musculus 17-21 3258857-6 1988 The cyclic adenosine monophosphate (cAMP)-elevating agents prostaglandin E2, dibutyryl cAMP, and theophylline inhibited IL-2 production during the early, IL-1-dependent programming stage. Cyclic AMP 87-91 interleukin 2 Mus musculus 120-124 3040863-0 1987 Effects of anti-proliferative cyclic AMP on interleukin 2-stimulated gene expression. Cyclic AMP 30-40 interleukin 2 Mus musculus 44-57 3040863-2 1987 The effects of antiproliferative dosages of stable cAMP-derivative, 8-bromoadenosine 3":5"-monophosphate (8-Br-cAMP), on steady state mRNA expression stimulated by IL-2 was examined. Cyclic AMP 51-55 interleukin 2 Mus musculus 164-168 3040863-9 1987 cAMP, therefore, acts on multiple targets involved in the macromolecular events stimulated by IL-2. Cyclic AMP 0-4 interleukin 2 Mus musculus 94-98 3258857-6 1988 The cyclic adenosine monophosphate (cAMP)-elevating agents prostaglandin E2, dibutyryl cAMP, and theophylline inhibited IL-2 production during the early, IL-1-dependent programming stage. Cyclic AMP 4-34 interleukin 2 Mus musculus 120-124 3258857-6 1988 The cyclic adenosine monophosphate (cAMP)-elevating agents prostaglandin E2, dibutyryl cAMP, and theophylline inhibited IL-2 production during the early, IL-1-dependent programming stage. Cyclic AMP 36-40 interleukin 2 Mus musculus 120-124 3005278-3 1986 In intact cells, IL 2 inhibited both basal and PGE2-stimulated cAMP production; the amount of cAMP generated was dependent upon the relative concentrations of IL 2 and PGE2. Cyclic AMP 94-98 interleukin 2 Mus musculus 17-21 3005278-3 1986 In intact cells, IL 2 inhibited both basal and PGE2-stimulated cAMP production; the amount of cAMP generated was dependent upon the relative concentrations of IL 2 and PGE2. Cyclic AMP 94-98 interleukin 2 Mus musculus 159-163 3005278-4 1986 The effect of IL 2 on CT6 cell proliferation and cAMP production was mimicked by the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), which, like IL 2, causes a translocation and activation of protein kinase C. While PGE2 stimulated adenylate cyclase activity in membrane preparations, neither IL 2 nor TPA inhibited either basal or stimulated membrane adenylate cyclase activity. Cyclic AMP 49-53 interleukin 2 Mus musculus 14-18 3005278-7 1986 The data suggest that the decreased cAMP production which accompanies CT6 cell proliferation results from an inhibition of adenylate cyclase activity mediated by protein kinase C and that these two distinct protein phosphorylating systems interact to modulate the physiological response to IL 2. Cyclic AMP 36-40 interleukin 2 Mus musculus 290-294 25817470-0 2015 Interleukin-2 treatment reverses effects of cAMP-responsive element modulator alpha-over-expressing T cells in autoimmune-prone mice. Cyclic AMP 44-48 interleukin 2 Mus musculus 0-13 29515759-4 2018 Here we show that an enhanced NFATc1 activity induced by increased integrin-cAMP signaling plays a critical role in the dysregulation of Klf1 expression and thereby cause anemia in Il2-/- mice. Cyclic AMP 76-80 interleukin 2 Mus musculus 181-184 29515759-7 2018 Restoring IL-2 signaling in Il2-/- mice reversed the increase in cAMP-NFAT signaling and facilitated normal erythropoiesis. Cyclic AMP 65-69 interleukin 2 Mus musculus 10-14 29515759-7 2018 Restoring IL-2 signaling in Il2-/- mice reversed the increase in cAMP-NFAT signaling and facilitated normal erythropoiesis. Cyclic AMP 65-69 interleukin 2 Mus musculus 28-31